Does the media prefer AQST or LENZ?

In the previous week, Aquestive Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 5 mentions for LENZ Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.83 beat LENZ Therapeutics' score of 0.75 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CRMD or LENZ?

In the previous week, CorMedix had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for CorMedix and 5 mentions for LENZ Therapeutics. CorMedix's average media sentiment score of 1.07 beat LENZ Therapeutics' score of 0.75 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CTNM or LENZ?

In the previous week, LENZ Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 4 mentions for Contineum Therapeutics. LENZ Therapeutics' average media sentiment score of 0.75 beat Contineum Therapeutics' score of 0.55 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EOLS or LENZ more profitable?

Evolus has a net margin of -10.85% compared to LENZ Therapeutics' net margin of -586.74%. Evolus' return on equity of 0.00% beat LENZ Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -10.85% N/A -13.00% LENZ Therapeutics -586.74% -53.39% -49.14%

Does the media prefer EOLS or LENZ?

In the previous week, Evolus had 4 more articles in the media than LENZ Therapeutics. MarketBeat recorded 9 mentions for Evolus and 5 mentions for LENZ Therapeutics. Evolus' average media sentiment score of 0.88 beat LENZ Therapeutics' score of 0.75 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LENZ Therapeutics (LENZ) Competitors

$4.52 -0.20 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$4.59 +0.07 (+1.46%)

As of 07:55 PM Eastern

Compare

LENZ vs. AQST, DRUG, CRMD, CTNM, and EOLS

Should you buy LENZ Therapeutics stock or one of its competitors? LENZ Therapeutics's main competitors and comparable companies include Aquestive Therapeutics (AQST), Bright Minds Biosciences (DRUG), CorMedix (CRMD), Contineum Therapeutics (CTNM), and Evolus (EOLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does LENZ Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

LENZ Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$54.09M	11.09	-$83.78M	-$0.65	N/A
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A

Aquestive Therapeutics has a net margin of -144.63% compared to LENZ Therapeutics' net margin of -586.74%. Aquestive Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-144.63%	N/A	-52.40%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Aquestive Therapeutics presently has a consensus price target of $9.17, suggesting a potential upside of 91.77%. LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 537.17%. Given LENZ Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aquestive Therapeutics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Aquestive Therapeutics had 3 more articles in the media than LENZ Therapeutics. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 5 mentions for LENZ Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.83 beat LENZ Therapeutics' score of 0.75 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aquestive Therapeutics beats LENZ Therapeutics on 11 of the 17 factors compared between the two stocks.

How does LENZ Therapeutics compare to Bright Minds Biosciences?

LENZ Therapeutics (NASDAQ:LENZ) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

In the previous week, LENZ Therapeutics had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for LENZ Therapeutics and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.96 beat LENZ Therapeutics' score of 0.75 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
Bright Minds Biosciences	Positive

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bright Minds Biosciences has lower revenue, but higher earnings than LENZ Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

LENZ Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, indicating that its stock price is 636% less volatile than the broader market.

LENZ Therapeutics currently has a consensus price target of $28.80, suggesting a potential upside of 537.17%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 127.66%. Given LENZ Therapeutics' higher probable upside, equities research analysts plainly believe LENZ Therapeutics is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bright Minds Biosciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Bright Minds Biosciences' return on equity of -12.46% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Summary

Bright Minds Biosciences beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

CorMedix currently has a consensus target price of $15.00, suggesting a potential upside of 91.82%. LENZ Therapeutics has a consensus target price of $28.80, suggesting a potential upside of 537.17%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

CorMedix has a net margin of 40.49% compared to LENZ Therapeutics' net margin of -586.74%. CorMedix's return on equity of 40.52% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

CorMedix has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.96	$163.05M	$2.14	3.65
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CorMedix had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 6 mentions for CorMedix and 5 mentions for LENZ Therapeutics. CorMedix's average media sentiment score of 1.07 beat LENZ Therapeutics' score of 0.75 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

CorMedix beats LENZ Therapeutics on 12 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Contineum Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Contineum Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A

Contineum Therapeutics presently has a consensus price target of $20.25, suggesting a potential upside of 36.64%. LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 537.17%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

54.3% of LENZ Therapeutics shares are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Contineum Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Contineum Therapeutics' return on equity of -24.73% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

In the previous week, LENZ Therapeutics had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 4 mentions for Contineum Therapeutics. LENZ Therapeutics' average media sentiment score of 0.75 beat Contineum Therapeutics' score of 0.55 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LENZ Therapeutics beats Contineum Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Evolus?

Evolus (NASDAQ:EOLS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Evolus has a net margin of -10.85% compared to LENZ Therapeutics' net margin of -586.74%. Evolus' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Evolus has higher revenue and earnings than LENZ Therapeutics. Evolus is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$316.49M	1.64	-$51.64M	-$0.52	N/A
LENZ Therapeutics	$19.09M	7.44	-$82.13M	-$4.09	N/A

In the previous week, Evolus had 4 more articles in the media than LENZ Therapeutics. MarketBeat recorded 9 mentions for Evolus and 5 mentions for LENZ Therapeutics. Evolus' average media sentiment score of 0.88 beat LENZ Therapeutics' score of 0.75 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolus currently has a consensus target price of $14.50, indicating a potential upside of 84.95%. LENZ Therapeutics has a consensus target price of $28.80, indicating a potential upside of 537.17%. Given LENZ Therapeutics' higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

90.7% of Evolus shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evolus has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Evolus beats LENZ Therapeutics on 10 of the 15 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LENZ vs. The Competition

Export

Metric	LENZ Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$142.02M	$12.35B	$7.12B	$12.83B
Dividend Yield	N/A	2.62%	2.56%	10.57%
P/E Ratio	-1.11	797.20	273.26	25.18
Price / Sales	7.44	790.67	638.34	89.67
Price / Cash	N/A	90.55	77.33	51.83
Price / Book	0.50	10.39	10.33	6.20
Net Income	-$82.13M	$2.82B	$3.49B	$358.38M
7 Day Performance	-24.16%	-3.54%	-3.29%	-2.35%
1 Month Performance	-13.24%	1.28%	-0.26%	-2.61%
1 Year Performance	-88.92%	2.81%	17.32%	8.08%

LENZ Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LENZ LENZ Therapeutics	3.3464 of 5 stars	$4.52 -4.2%	$28.80 +537.2%	-88.7%	$142.02M	$19.09M	N/A	110	Analyst Downgrade
AQST Aquestive Therapeutics	2.5741 of 5 stars	$5.21 -2.4%	$8.80 +68.9%	+2.3%	$653.92M	$54.09M	N/A	160	Analyst Forecast
DRUG Bright Minds Biosciences	2.8993 of 5 stars	$66.91 +2.7%	$143.83 +115.0%	+54.1%	$651.03M	N/A	N/A	N/A	Positive News
CRMD CorMedix	3.346 of 5 stars	$8.18 -3.0%	$15.00 +83.4%	-37.8%	$637.55M	$311.71M	3.82	30	Positive News
CTNM Contineum Therapeutics	1.7126 of 5 stars	$15.94 -4.6%	$20.25 +27.0%	+24.2%	$599.68M	N/A	N/A	31	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENZ Therapeutics (LENZ) Competitors

LENZ vs. AQST, DRUG, CRMD, CTNM, and EOLS

How does LENZ Therapeutics compare to Aquestive Therapeutics?

Summary

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Summary

How does LENZ Therapeutics compare to CorMedix?

Summary

How does LENZ Therapeutics compare to Contineum Therapeutics?

Summary

How does LENZ Therapeutics compare to Evolus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENZ Therapeutics (LENZ) Competitors

LENZ vs. AQST, DRUG, CRMD, CTNM, and EOLS

How does LENZ Therapeutics compare to Aquestive Therapeutics?

Which has better earnings & valuation, AQST or LENZ?

Is AQST or LENZ more profitable?

Do analysts recommend AQST or LENZ?

Which has more volatility and risk, AQST or LENZ?

Does the media prefer AQST or LENZ?

Do institutionals and insiders hold more shares of AQST or LENZ?

Summary

How does LENZ Therapeutics compare to Bright Minds Biosciences?

Does the media refer more to LENZ or DRUG?

Do insiders & institutionals hold more shares of LENZ or DRUG?

Which has better earnings and valuation, LENZ or DRUG?

Which has more risk and volatility, LENZ or DRUG?

Do analysts recommend LENZ or DRUG?

Is LENZ or DRUG more profitable?

Summary

How does LENZ Therapeutics compare to CorMedix?

Do analysts rate CRMD or LENZ?

Is CRMD or LENZ more profitable?

Which has preferable valuation & earnings, CRMD or LENZ?

Do insiders and institutionals hold more shares of CRMD or LENZ?

Does the media prefer CRMD or LENZ?

Which has more risk and volatility, CRMD or LENZ?

Summary

How does LENZ Therapeutics compare to Contineum Therapeutics?

Which has more volatility and risk, CTNM or LENZ?

Which has better valuation & earnings, CTNM or LENZ?

Do analysts prefer CTNM or LENZ?

Do institutionals and insiders hold more shares of CTNM or LENZ?

Is CTNM or LENZ more profitable?

Does the media refer more to CTNM or LENZ?

Summary

How does LENZ Therapeutics compare to Evolus?

Is EOLS or LENZ more profitable?

Which has preferable valuation and earnings, EOLS or LENZ?

Does the media prefer EOLS or LENZ?

Do analysts rate EOLS or LENZ?

Do institutionals & insiders have more ownership in EOLS or LENZ?

Which has more risk and volatility, EOLS or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools